CIM
SCLN

Cambria Investment Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Cambria Investment Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,776
Closed -$19K – 312
2015
Q3 		$19K Buy
+2,776
New +$23.8K 0.01% 233

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cambria Investment Management's SCLN Position: Q4 2015 in Review

Cambria Investment Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2015, closing a stake of 2,776 shares — an estimated $19K sold.

Cambria Investment Management first reported a position in SCLN in Q3 2015 and held it in 1 quarter. The position peaked at $19K in Q3 2015. 133 funds tracked by Wall St. Rank hold SCLN as of Q4 2015.

  • Cambria Investment Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Cambria Investment Management sold 2,776 Sciclone Pharmaceuticals Inc shares in Q4 2015, an estimated $19K.
  • Cambria Investment Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2015 and held it in 1 quarter.
  • Cambria Investment Management's Sciclone Pharmaceuticals Inc position peaked at $19K in Q3 2015.
  • 133 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2015.

Based on Cambria Investment Management's 13F filing for Q4 2015, filed 11 Feb 2016.